Adding to the Mix

New strategies are positioning MDA's research program for success

by Amy Madsen on January 1, 2008 - 3:06pm

QUEST Vol. 15, No. 1

The fast pace of scientific progress in this first decade of the 21st century, coupled with expanding knowledge about human genetics and disease, has led to significant changes in the way MDA approaches research.

For the past 50 years, MDA’s basic laboratory research program has uncovered critical information about the genetic defects underlying neuromuscular diseases. This information has opened the possibility of developing drug therapies aimed at specific genetic targets.

To translate this possibility into reality, in 2004 MDA initiated its translational research program, with the goal of fast-tracking promising findings from the lab to clinical trials.

Sharon Hesterlee, MDA Vice President of Translational Research

“The research program is evolving to take advantage of the strengths of everyone involved in the search for cures, from investigators and research teams to investors, to pharmaceutical and biotechnology companies large and small, to other health organizations and to those with neuromuscular diseases,” says MDA Vice President of Translational Research Sharon Hesterlee.

A big part of that evolution has been the translational program. It doesn’t replace but complements the basic research model already in place, putting more methods at MDA’s disposal for finding treatments and cures.

The basics and beyond

The difference between MDA’s translational and basic research programs is the difference between “top-down” and “bottom-up” approaches to research.

The bottom-up approach fuels discovery in the basic research program, where projects advancing basic science and generating ideas for potential drug therapies are initiated by the researchers themselves. These applications are reviewed by MDA’s Scientific or Medical Advisory Committees (SAC or MAC), and then approved by MDA’s Board of Directors.

“In the basic research program, the goal is to fund the best research and the best ideas out there without dictating where they come from,” Hesterlee says. “There’s merit in that strategy — with its less-directed approach, we’ve fielded good ideas from unpredictable places.”

In contrast, the translational top-down model allows MDA to exert more control as it capitalizes on all the successful research it has funded over the years and pursues the most promising avenues in drug development research.

“‘Top-down’ means we decide what areas we’re interested in and what we want to study,” Hesterlee says. “We can’t be passive — good ideas come from unsolicited proposals, but with drug development, you want more control.”

Translational grants

The translational research program awards four types of grants to help overcome obstacles hindering preclinical therapy development and early-phase clinical research for new drugs (or new applications for existing drugs).

Infrastructure grants fund the development of tools, techniques and services, such as animal facilities or collections of immune-system proteins, that benefit neuromuscular disease research and that typically aren’t eligible for funding from other sources.

PTC Therapeutics in South Plainfield, N.J.

Clinical research training grants address the need for clinicians with the proper training and experience to plan and run effective clinical trials.

“It was clear there was a lack of trained clinical investigators who could do clinical trials,” Hesterlee explains. “Clinicians have to have a lot of experience in areas such as statistics, and U.S. Food and Drug Administration and university regulations, and they need to know how to design a trial and run it efficiently.”

The clinical research training grant satisfies that need by funding a two-year program in which physicians take courses in areas such as epidemiology, clinical statistics and trial design for one year, followed by participation in a clinical research project the second year.

Investigational new drug (IND) planning grants fund academic research on potential therapies at the point where they look promising in an animal model and are ready to be developed into a drug. (An IND is a drug that has never been tested in humans before.) IND planning grants fund all the steps required before the FDA will approve testing in humans: toxicology, manufacturing, some optimization (finding the best formulation for a compound), and scale-up (increasing production from laboratory scale to the levels needed for clinical development).

Corporate grants are used to fund companies directly. Contracts govern the arrangements and typically include royalty-sharing agreements. Projects also are “milestone-driven” — if goals aren’t achieved as stipulated in the contract, MDA is not obligated to pay.

“We want to make sure there is an increased level of accountability now for these projects,” says Cristina Csimma, principal at Clarus Ventures, a venture capital firm with a focus on life sciences in Cambridge, Mass.

Csimma, a member of MDA’s Translational Research Advisory Committee (TRAC) since August 2006, observes that funding projects that don’t reach conclusion “takes away resources from a project that could have been funded.”

All translational grant applications are reviewed by two experts in the field, and then passed along to the TRAC, which asks applicants to make personal presentations. The TRAC makes funding recommendations to MDA’s Board of Directors, which makes the final decision.

From top to bottom

There are real advantages to having both kinds of research programs.

“We’re kind of hedging our bets,” says Hesterlee. In translational research, “we’re taking advantage of the ability to direct some aspects of our program, but at the same time [in basic science research] we’re casting a wide net, and looking for unexpected things we might not know about otherwise.”

Hesterlee notes that MDA’s goal is “not just to fund research and get the drug fairy to make drugs — we have to be actively involved in that process, managing it from beginning to end to make sure nothing falls through the cracks.

“We don’t want anything to stall because there’s not a hand-off to the next stage. We want to make sure we see the whole thing through. What people and their families want to know is, who’s in charge of curing my disease? And at MDA that’s our mission. Our goal is to cure diseases.”

Your rating: None Average: 4 (1 vote)
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email See comment policy